The Award
This award recognises a private CEO that has demonstrated truly outstanding and exemplary leadership of a privately-owned life science company. This category is a peer-to-peer award with votes having originated from the attending executives.
Company Description
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules TCER®. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology. Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.
© 2018 All Rights Reserved By LSX Ltd (formerly Biotech and Money Ltd)